These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12666192)

  • 1. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).
    Gansbacher B;
    J Gene Med; 2003 Mar; 5(3):261-2. PubMed ID: 12666192
    [No Abstract]   [Full Text] [Related]  

  • 2. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
    European Society of Gene Therapy
    J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene therapy for severe combined immune deficiency.
    Qasim W; Gaspar HB; Thrasher AJ
    Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of leukaemia following gene therapy of X-linked SCID.
    Kohn DB; Sadelain M; Glorioso JC
    Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter to the editors of Nature from the American Society of Gene Therapy (ASGT) and the European Society of Gene Therapy (ESGT).
    Kohn DB; Gänsbacher B
    J Gene Med; 2003 Jul; 5(7):641. PubMed ID: 12825204
    [No Abstract]   [Full Text] [Related]  

  • 6. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
    N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
    Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
    Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy: therapeutic gene causing lymphoma.
    Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
    Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene therapy of children with X-linked severe combined immune deficiency: efficiency and complications].
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    Med Sci (Paris); 2004 Jan; 20(1):115-7. PubMed ID: 14770374
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene therapy. Second child in French trial is found to have leukemia.
    Marshall E
    Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene therapy. Panel urges limits on X-SCID trials.
    Kaiser J
    Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
    [No Abstract]   [Full Text] [Related]  

  • 12. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
    Kaiser J
    Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy on trial.
    Hughes V
    Nat Med; 2007 Sep; 13(9):1008-9. PubMed ID: 17828211
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene therapy: X-SCID transgene leukaemogenicity.
    Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
    Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
    Buchholz CJ; Cichutek K
    J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success and setback: another adverse event.
    Verma IM
    Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
    Couzin J; Kaiser J
    Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
    [No Abstract]   [Full Text] [Related]  

  • 18. [A third tumor following SCID gene therapy].
    Winckler T
    Pharm Unserer Zeit; 2005; 34(3):184-5. PubMed ID: 15940949
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicine. Gene therapy--new challenges ahead.
    Williams DA; Baum C
    Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene therapy].
    Demonté D; Van Lint C; Burny A
    Rev Med Brux; 2002 Sep; 23(4):A331-4. PubMed ID: 12422456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.